Pembrolizumab (Keytruda)
Anti-PD-1 immunotherapy checkpoint inhibitor approved for many cancer types including melanoma, lung, and gastric cancers.
What is Pembrolizumab?
What it targets
Blocks PD-1 on T cells, preventing interaction with PD-L1/PD-L2 on cancer cells, thereby reactivating anti-tumor immune responses and enabling durable cancer control.
Who it may help
Patients with confirmed biomarker status (PD-L1 expression, MSI-H/dMMR, or TMB-H), adequate organ function, and cancers approved for Pembrolizumab in their specific disease stage and treatment line.
Why testing matters
PD-L1, MSI/dMMR, and molecular testing guide eligibility and predict likelihood of response. Baseline labs, imaging, and organ function assessment ensure safety and enable dose optimization.
Which cancers can Pembrolizumab treat?
Pembrolizumab has FDA approval for many cancer types in first-line, later-line, adjuvant, neoadjuvant, and maintenance settings. Specific indications, combination partners, and biomarker requirements vary by cancer type and regulatory jurisdiction.
| Non-small cell lung cancer (NSCLC) | First-line single-agent (PD-L1 TPS ≥1%), first-line with chemotherapy (non-squamous with pemetrexed), later-line after platinum progression, neoadjuvant/adjuvant (resectable ≥4 cm or node-positive), maintenance after chemoradiotherapy in unresectable stage III. |
| Melanoma (unresectable/metastatic) | Single-agent treatment for advanced disease; neoadjuvant/adjuvant in high-risk resectable melanoma; often combined with ipilimumab in certain settings. |
| Head and neck squamous cell carcinoma (HNSCC) | First-line (PD-L1 CPS ≥1%), later-line after platinum progression (any PD-L1), resectable locally advanced disease, combination with chemoradiotherapy, combination with Padcev in selected settings. |
| Gastric and gastroesophageal junction (GEJ) cancer | First-line with chemotherapy ± trastuzumab (HER2-positive); later-line; neoadjuvant/adjuvant combinations depending on biomarker status and regional approval. |
| Urothelial carcinoma (bladder cancer) | Advanced/metastatic disease; neoadjuvant/adjuvant for muscle-invasive bladder cancer (with or without Padcev); non-muscle-invasive disease; combination with enfortumab vedotin for advanced disease. |
| Cervical cancer | Persistent/recurrent/metastatic disease, locally advanced settings; combination with chemoradiotherapy, bevacizumab, or chemotherapy depending on indication and stage. |
| Renal cell carcinoma (RCC) | Advanced/metastatic disease typically with axitinib or lenvatinib; adjuvant treatment (intermediate-high or high risk) with belzutifan (Welireg) as of June 2026. |
| Hepatocellular carcinoma (HCC) | Advanced disease in selected patients; may be combined with other therapies depending on local approval and specialist assessment. |
| Triple-negative breast cancer (TNBC) | Locally advanced/metastatic disease with PD-L1 expression; neoadjuvant/adjuvant in early-stage high-risk disease; combination with chemotherapy in perioperative settings. |
| Endometrial cancer | Advanced or recurrent disease; first-line with carboplatin/paclitaxel (2024 approval); MSI-H/dMMR single-agent options; later-line combinations. |
| Esophageal cancer | Locally advanced, unresectable, recurrent, or metastatic disease; typically combined with chemotherapy; biomarker-selected settings. |
| MSI-H/dMMR solid tumors (tumor-agnostic) | Unresectable or metastatic solid tumors with MSI-H or mismatch repair deficiency; approved for both adult and pediatric patients after prior treatment when alternatives limited. |
| Colorectal cancer (CRC) | MSI-H/dMMR first-line and later-line; metastatic or locally advanced disease; often combined with chemotherapy depending on indication. |
| Classical Hodgkin lymphoma | Relapsed or refractory disease; approved in both adult and pediatric populations; monotherapy in most settings. |
| Primary mediastinal B-cell lymphoma (PMBCL) | Relapsed or refractory disease; often considered after 2 or more prior lines of therapy depending on approval and ECOG status. |
| Biliary tract cancer | Advanced or unresectable/metastatic disease; typically combined with gemcitabine and cisplatin; later-line options in selected settings. |
| Merkel cell carcinoma (MCC) | Recurrent locally advanced or metastatic disease; approved for both adjuvant and advanced metastatic settings depending on stage. |
| Ovarian/fallopian tube/peritoneal cancer | Platinum-resistant epithelial ovarian cancer (February 2026): combined with paclitaxel and bevacizumab (PD-L1 CPS ≥1, post 1-2 lines of prior therapy). |
| Malignant pleural mesothelioma (MPM) | Advanced unresectable or metastatic disease; approved with pemetrexed and platinum chemotherapy as first-line (September 2024 approval). |
Are you eligible for Pembrolizumab?
Eligibility depends on confirmed cancer diagnosis, disease stage, treatment line, biomarker status (PD-L1, MSI-H/dMMR, or TMB-H in relevant indications), prior treatment history, organ function, and overall performance status. Your oncologist will assess suitability based on current disease burden and health status.
- Confirmed malignancy on biopsy with appropriate histopathology or cytology
- Disease stage meeting approval criteria (metastatic, locally advanced, resectable, or recurrent depending on indication)
- Biomarker testing completed (PD-L1 by IHC if required for your cancer type; MSI/dMMR testing if tumor-agnostic indication considered)
- Adequate liver function (ALT, AST, bilirubin within acceptable limits)
- Adequate kidney function (creatinine clearance and glomerular filtration rate within acceptable range)
- Adequate bone marrow function (platelet count, hemoglobin, white blood cell count within acceptable limits)
- ECOG performance status 0 or 1 (ability to perform daily activities with minimal assistance)
- No active uncontrolled infection or untreated brain metastases without prior local treatment
- No history of severe autoimmune disease uncontrolled by standard therapy (varies by condition)
- Prior treatment must meet criteria for your indication (first-line, second-line, adjuvant, or other as specified)
How does Pembrolizumab work?
- PD-1 pathway blockade
- T-cell reactivation
- Anti-tumor immune attack
- Potential for durable response
Pembrolizumab works by 'releasing the brakes' on the immune system, allowing T cells to attack cancer cells that had learned to hide.
Tests required before starting Pembrolizumab
Comprehensive testing before Pembrolizumab confirms eligibility, guides dose adjustments, detects baseline organ function issues, and establishes treatment baseline for monitoring response and toxicity.
| Complete Blood Count (CBC) | Baseline hemoglobin, platelet count, white blood cell count; monitors for anemia, thrombocytopenia, or immune suppression during treatment. |
| Comprehensive Metabolic Panel (CMP) | Liver function (ALT, AST, bilirubin, albumin), kidney function (creatinine, BUN), electrolytes; essential for dose safety and detecting baseline impairment. |
| PD-L1 testing by IHC | Determines PD-L1 expression level (TPS or CPS score) when relevant for your cancer type; guides treatment selection and predicts response likelihood. |
| MSI/dMMR testing | Identifies tumors with microsatellite instability or mismatch repair deficiency; enables tumor-agnostic indication and predicts sensitivity to Pembrolizumab. |
| Next-generation sequencing (NGS) / Molecular testing | Identifies EGFR, ALK, ROS1, BRAF, KRAS, NRAS, NTRK, PD-L1, TMB, or other driver mutations; guides targeted or combination therapy decisions. |
| Thyroid function (TSH, free T4) | Baseline assessment; Pembrolizumab may cause thyroid dysfunction; baseline values enable early detection of immune-mediated thyroiditis. |
| Hepatitis B, Hepatitis C, HIV screening | Baseline serology to assess infection risk; HBV reactivation is a known risk; baseline HIV count guides management if immunosuppression needed. |
| Pregnancy test (if applicable) | Pembrolizumab is contraindicated in pregnancy; confirmed negative status required before start in women of childbearing age. |
| Baseline imaging (CT, MRI, or PET-CT) | Establishes tumor burden, extent of disease, presence of brain/organ metastases; enables response assessment at follow-up scans. |
| Autoimmune disease history review | Assessment of prior autoimmune conditions, ongoing immunosuppression, or prior immunotherapy toxicity; guides baseline risk stratification. |
How is Pembrolizumab given?
Pembrolizumab is administered by trained oncology staff. Two formulations are available: standard intravenous infusion (30 minutes) or newer subcutaneous injection (1-2 minutes). Dosing and scheduling depend on cancer type, indication, and treatment line.
| Intravenous dosing standard | 200 mg IV every 3 weeks (Q3W) or 400 mg IV every 6 weeks (Q6W); fixed-dose regimen not weight-based. |
| Subcutaneous dosing (Keytruda Qlex) | 395 mg or 790 mg subcutaneously every 3 weeks or every 6 weeks (approved September 2025); same efficacy and safety as IV with greater convenience. |
| Infusion administration | Intravenous infusion given over 30 minutes in infusion center, hospital, or qualified office setting; subcutaneous injection takes 1-2 minutes and may be given in office, clinic, or patient home settings. |
| Typical treatment duration | Continuous dosing for 2 years (approximately 35 cycles Q3W or 17 cycles Q6W) unless disease progresses or intolerable toxicity develops; some indications may allow discontinuation earlier or continuation beyond 2 years. |
| Combination settings | Often combined with chemotherapy (pemetrexed, platinum, paclitaxel, fluoropyrimidines), targeted therapy (axitinib, lenvatinib, belzutifan), antibody-drug conjugates (enfortumab vedotin), or other immunotherapies (ipilimumab) depending on indication. |
| Missed or delayed dose | If a scheduled infusion is missed, contact your oncology team immediately; timing adjustments may be made to maintain treatment schedule continuity. |
Clinical evidence and benefits
Pembrolizumab has demonstrated clinical benefit across many cancer types through landmark trials and real-world data. Response rates, duration of response, and survival improvements vary by cancer type, biomarker status, and treatment setting.
| Melanoma (advanced) | Substantial objective response rates in single-agent setting; many patients achieve durable remissions; adjuvant use in high-risk resectable disease significantly reduces recurrence risk. |
| NSCLC (PD-L1 high) | Superior progression-free and overall survival versus chemotherapy in first-line PD-L1 ≥50% disease; extended 6-week dosing maintains efficacy with fewer clinic visits. |
| Head and neck cancer | Significant improvement in progression-free survival and overall survival versus cetuximab in platinum-refractory disease; benefit extends to earlier lines with PD-L1 testing. |
| Gastric/GEJ cancer | Added to chemotherapy improves overall survival in first-line treatment; benefit consistent across HER2 status and regional populations. |
| MSI-H/dMMR solid tumors (tumor-agnostic) | Landmark approval based on objective response rates and durability across diverse tumor types; demonstrates that certain biomarkers predict response independent of cancer origin. |
| Survival improvement qualitative | Substantially improved overall survival compared to previous standard of care across approved indications; median survival improvements vary (typically months to years depending on cancer type). |
| Durable response potential | Subset of patients achieve long-lasting responses; some continue disease control after treatment discontinuation; durability supports potential for curative intent in selected cases. |
| Quality of life benefit | Generally better tolerated than chemotherapy; oral and subcutaneous formulations reduce treatment burden; extended dosing intervals (Q6W) provide patient convenience. |
Individual responses vary significantly. These benefits represent published clinical trial data. Your oncologist will discuss expected outcomes, response timelines, and alternatives specific to your cancer type, stage, and biomarker profile.
Side effects of Pembrolizumab
Most common side effects are manageable; however, Pembrolizumab can cause serious immune-mediated adverse reactions (irAEs) affecting multiple organ systems. These may develop during treatment or weeks to months after discontinuation. Close medical monitoring is essential.
| Fatigue | Very common; occurs in majority of patients; usually mild to moderate, manageable with rest and supportive care. |
| Musculoskeletal pain (arthralgia, myalgia) | Common; may affect joints or muscles; managed with analgesics, physical therapy, or temporary treatment pause. |
| Skin rash and pruritus (itching) | Very common; usually mild to moderate and reversible; may require topical corticosteroids or dermatology evaluation. |
| Diarrhea | Common; usually mild; managed with dietary modification, anti-diarrheal agents, or fluid replacement; severe diarrhea requires evaluation. |
| Nausea and vomiting | Common; usually manageable with antiemetics; typically improves over time. |
| Decreased appetite | Occurs in many patients; nutritional support and dietary adjustments help maintain caloric intake. |
| Cough and dyspnea | Reported in significant percentage; must be evaluated promptly to exclude immune-mediated pneumonitis. |
| Headache and dizziness | Less common but reported; usually mild; must be monitored as serious neurologic irAEs are rare. |
| Fever | May occur; usually mild; persistent or high fever warrants investigation. |
| Anemia (low hemoglobin) | Laboratory finding in subset of patients; may cause fatigue; monitored by CBC; rarely requires intervention. |
| Hypothyroidism (low thyroid function) | Most common immune-mediated endocrine event; detected by TSH elevation; managed with levothyroxine replacement. |
| Hyperthyroidism (overactive thyroid) | Less common than hypothyroidism; may precede hypothyroidism; managed with beta-blockers and monitoring. |
| Vitiligo (skin depigmentation) | Uncommon; depigmentation of skin or mucosal areas; cosmetic concern; associated with favorable prognosis in melanoma. |
Contact your doctor immediately if you develop:
- Severe shortness of breath, chest pain, or persistent cough (possible pneumonitis)
- Severe abdominal pain, persistent diarrhea, or blood in stool (possible colitis)
- Yellowing of skin or eyes, severe fatigue, or dark urine (possible hepatitis)
- Severe headache, confusion, vision changes, or difficulty speaking (possible neurologic toxicity)
- Severe rash covering large body surface or blistering involving mouth or genitals (possible Stevens-Johnson or severe skin reaction)
- Severe muscle pain or weakness preventing movement (possible myositis)
- Pounding heartbeat, heat intolerance, or sweating (possible thyroid storm)
- Unexplained high fever (>101.5°F), chills, or signs of infection
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medications, supplements, herbal products, prior treatments, and medical conditions. Certain conditions and drug combinations may increase Pembrolizumab toxicity risk or reduce effectiveness.
- Live vaccines are contraindicated; inactivated vaccines may be less effective during immunotherapy; discuss vaccination timing with your oncologist.
- Corticosteroid use at baseline may reduce Pembrolizumab effectiveness; inform your team if you take any steroids before starting therapy.
- Severe autoimmune disease (uncontrolled lupus, rheumatoid arthritis, vasculitis) increases irAE risk; discuss disease control options with your rheumatologist before Pembrolizumab.
- Prior allogeneic stem cell transplantation carries increased risk of graft-versus-host disease (GVHD) reactivation; requires careful monitoring and possible dose adjustment.
- Hepatitis B surface antigen positive status requires monitoring for HBV reactivation; antiviral prophylaxis may be recommended.
- Hepatitis C antibody positivity requires baseline viral load assessment and monitoring during treatment.
- HIV-positive patients on antiretroviral therapy may safely receive Pembrolizumab; CD4 count monitoring is recommended.
- Tuberculosis history (latent or prior treated): TB reactivation risk exists; baseline testing and consideration of TB prophylaxis may be needed.
- No major CYP450 enzyme interactions identified; Pembrolizumab metabolism not affected by common CYP inhibitors or inducers.
- Pregnancy and breastfeeding contraindicated; effective contraception required for women and men of reproductive potential.
Pembrolizumab combination treatments
Pembrolizumab is frequently combined with chemotherapy, targeted therapy, other immunotherapies, or antibody-drug conjugates to improve response rates and overcome resistance. Specific combinations are approved for different cancer types and treatment settings.
| Pembrolizumab + chemotherapy (NSCLC) | Pemetrexed and platinum for non-squamous; platinum for squamous cell; demonstrated superior survival versus chemotherapy alone; standard first-line regimen. |
| Pembrolizumab + chemotherapy (gastric cancer) | Fluoropyrimidine and platinum-based chemotherapy; improves overall survival in first-line treatment for advanced/metastatic HER2-negative disease. |
| Pembrolizumab + bevacizumab (cervical cancer) | Combined with bevacizumab for recurrent/metastatic disease; enhances anti-tumor activity through dual pathway blockade. |
| Pembrolizumab + enfortumab vedotin (urothelial carcinoma) | Approved for advanced metastatic disease; also approved as neoadjuvant/adjuvant (with cystectomy) for muscle-invasive bladder cancer (November 2025). |
| Pembrolizumab + axitinib or lenvatinib (RCC) | Targets both immune and angiogenic pathways; approved for advanced renal cell carcinoma; substantially improves progression-free survival. |
| Pembrolizumab + belzutifan (RCC adjuvant) | First PD-1/HIF-2α inhibitor combination (June 2026); approved for adjuvant treatment of ccRCC at intermediate-high or high recurrence risk. |
| Pembrolizumab + ipilimumab (melanoma) | Dual checkpoint blockade (PD-1 + CTLA-4); most effective combination in advanced melanoma; increased response rates offset by higher irAE rates. |
| Pembrolizumab + chemotherapy + paclitaxel (ovarian cancer) | With or without bevacizumab; approved February 2026 for platinum-resistant epithelial ovarian, fallopian tube, or peritoneal carcinoma (PD-L1 CPS ≥1). |
| Pembrolizumab + pemetrexed + platinum (mesothelioma) | Three-drug combination approved September 2024 for unresectable/metastatic malignant pleural mesothelioma. |
| Pembrolizumab monotherapy switching | Single-agent Pembrolizumab after combination induction is standard in many settings; reduces toxicity while maintaining benefit. |
If Pembrolizumab stops working
Primary or acquired resistance can develop. Understanding resistance mechanisms guides next-line treatment selection and clinical trial evaluation. Your oncologist will recommend repeat testing, imaging, and individualized next steps.
| Primary resistance (lack of initial response) | Occurs in 30-50% of patients across cancer types. Mechanisms include low PD-L1, high tumor mutational heterogeneity, exhausted T cells, cold tumor microenvironment, or immunosuppressive pathways (TIM-3, LAG-3, IDO). Requires repeat biomarker testing and consideration of alternative approaches. |
| Acquired resistance (progression after initial response) | Loss of response over time; may involve PD-L1 upregulation, immune checkpoint suppression, tumor heterogeneity evolution, or T-cell exhaustion. Repeat biopsy and NGS can identify new mutations (JAK1/JAK2 loss-of-function, PTEN loss) guiding next therapy. |
| PD-L1 testing at progression | Repeat PD-L1 IHC or other biomarker testing; upregulation may predict response to second-line immunotherapy combinations. |
| Next-line chemotherapy options | Cytotoxic chemotherapy; platinum-doublet combinations; regimens tailored to prior exposure and cancer type. |
| Next-line targeted therapy | EGFR, ALK, ROS1, BRAF, KRAS, or other driver-specific drugs if mutations identified; may be more effective than additional immunotherapy in some contexts. |
| Antibody-drug conjugate (ADC) options | Enfortumab vedotin, sacituzumab govitecan, trastuzumab deruxtecan, or others depending on cancer type and target expression. |
| Clinical trial evaluation | Investigational combinations, novel checkpoint inhibitors (LAG-3, TIM-3, TIGIT agents), bispecific antibodies, or cellular therapies may be appropriate. |
| Supportive and palliative care | Focus shifts to symptom management, quality of life, and psychosocial support; may include radiation, surgery, or other local interventions depending on sites of progression. |
Cost of Pembrolizumab by country
Pembrolizumab cost varies dramatically by country, formulation, dose schedule, number of cycles, insurance status, and patient assistance program eligibility. Both branded and generic options (in jurisdictions where available) have different pricing.
| India | Generic Pembrolizumab 100 mg vials: approximately INR 25,000-45,000 per vial; branded Keytruda: INR 80,000-120,000 per vial. 2-year monotherapy course estimated INR 6-15 lakhs (USD 7,000-18,000). Patient assistance programs and state insurance (PMJAY, state schemes) may reduce cost. |
| USA | Branded Keytruda 100 mg vial: approximately USD 10,000-12,000 per 200 mg infusion. 2-year course estimated USD 200,000-250,000+. Insurance co-pays vary; patient assistance programs available. Biosimilar access improving cost landscape. |
| UK/Europe | NHS coverage in UK; availability and coverage in EU varies by country. Out-of-pocket cost in private settings similar to USA. NICE appraisals determine NHS funding; some countries negotiate pricing under EMA approval. |
| China | Branded Keytruda pricing negotiated; estimated CNY 15,000-25,000 per infusion; generics may be available; medical insurance and employer assistance programs common in major cities. |
| South Asia (Singapore, Malaysia, Thailand) | Ranging USD 8,000-15,000 per 2-year course depending on country, formulation, and insurance; medical tourism options available; generic versions emerging. |
Availability of Pembrolizumab globally
Pembrolizumab is available in most major oncology markets. Approval status, insurance coverage, pharmacy access, formulation options, and cost vary significantly by country and region.
India
Both branded Keytruda (Merck) and multiple generic manufacturers are available through oncology centers, private hospitals, and major pharmacies. PMJAY and state insurance schemes provide coverage for eligible patients.
USA
FDA-approved Keytruda and Keytruda Qlex (subcutaneous) are widely available at major cancer centers. Insurance coverage is standard for approved indications; Merck's patient assistance program helps uninsured patients.
UK
NICE-approved for multiple indications and available through the NHS, though some indications may need prior authorization. UK does not allow generic substitution for brand-name prescriptions.
European Union
EMA-approved Keytruda is available across EU member states. National health systems and insurance coverage vary by country, with established pricing in France, Germany, Spain, and Italy.
China
Approved for multiple indications; available in major cancer centers, hospitals, and specialty pharmacies. Insurance coverage varies by city and employer plan. Medical tourism options. Generic versions emerging as patents expire.
Canada
Health Canada approved; covered by provincial plans in most provinces. Private insurance typically covers approved indications. Access similar to USA; pricing slightly lower. Keytruda Qlex availability expanding.
Australia / New Zealand
Approved by TGA/MEDSAFE; covered under PBS (Australia) and PHARMAC (NZ) for approved indications with restrictions. Reliable access through major cancer centers. Private purchase available at higher cost.
Southeast Asia (Singapore, Thailand, Malaysia)
Approved in major markets; available through oncology centers, private hospitals, and specialty pharmacies. Insurance coverage varies; medical tourism common. Pricing higher than India but lower than Western countries.
Pembrolizumab in current clinical trials
Over 1,600 trials are actively investigating Pembrolizumab across cancer types, biomarker populations, treatment settings, and novel combinations. Trials are evaluating new indications, earlier treatment stages, combination strategies, and resistance mechanisms.
| Combination with LAG-3, TIM-3, TIGIT inhibitors | Next-generation checkpoint blockade combinations; addressing primary and acquired resistance; investigating dual or triple immune checkpoint combinations. |
| Pembrolizumab + novel chemotherapy agents | Testing combinations with non-traditional cytotoxics and novel agents; early-phase trials exploring synergy and tolerability. |
| Biomarker-driven trials (TMB-H, MSI-H/dMMR in new indications) | Expanding tumor-agnostic indications; investigating TMB-H beyond current approvals; studying MSI-H/dMMR solid tumors in underrepresented populations. |
| Neoadjuvant/adjuvant expansion studies | Earlier-stage disease; perioperative settings; combination with targeted therapy or other modalities; evaluating TFR (treatment-free remission) potential. |
| Pembrolizumab + targeted therapy combinations | BRAF/MEK, EGFR-TKI, ALK-TKI, ROS1-TKI combinations; studying synergy and overcoming resistance. |
| Pembrolizumab + cellular therapies | Combinations with CAR-T, TIL, or other cell therapies; early-phase exploration of dual immune activation. |
Your treatment journey with Pembrolizumab
Diagnosis, staging, and pathology review
Biomarker testing and molecular profiling
Initial oncology consultation and treatment planning
Pre-treatment baseline assessments
First Pembrolizumab infusion or injection
Early monitoring and side effect management (Cycles 1-3)
Response imaging and monitoring
Maintenance phase and ongoing monitoring
Treatment discontinuation or modification
Post-treatment follow-up and surveillance
Questions to ask your oncologist about Pembrolizumab
- Is Pembrolizumab appropriate for my specific cancer type, stage, and biomarker status?
- Do I need PD-L1 testing or other biomarker tests before starting Pembrolizumab?
- Will Pembrolizumab be used alone or in combination with chemotherapy or other drugs?
- How often will I receive Pembrolizumab, and how long will treatment continue?
- What are the most common side effects I should expect, and how are they managed?
- What serious side effects should I watch for, and when should I contact my doctor?
- Do I have autoimmune, lung, liver, kidney, or thyroid disease that affects my treatment safety?
- What blood tests and imaging will I need during treatment?
- Can I take vaccines while on Pembrolizumab?
- What is my expected response rate and timeline for seeing results?
- What are my options if Pembrolizumab does not work or stops working?
- What is the estimated total cost of Pembrolizumab treatment, and what assistance programs are available?
How CancerFax can help
CancerFax specializes in helping patients understand complex oncology treatments, navigate international access, and connect with specialists. We can support you throughout your Pembrolizumab journey.
| Biomarker report review | Our oncology specialists review your PD-L1, MSI/dMMR, and molecular testing reports to explain results and eligibility for Pembrolizumab. |
| Treatment plan review and second opinion | We provide medical review of your proposed Pembrolizumab regimen, recommend specialists, and offer alternatives if needed. |
| International treatment access (India, China, global) | CancerFax helps patients explore Pembrolizumab access in major cancer centers across India, China, and other countries where advanced treatment options are available. |
| Specialist connection and coordination | We connect you with medical oncologists, specialist centers, and clinical trials matching your cancer type and biomarker profile. |
| Cost estimation and payment options | We research regional pricing, insurance coverage, patient assistance programs, and payment plans to help you understand and manage treatment costs. |
| Clinical trial matching | Ongoing trials studying Pembrolizumab combinations, resistance mechanisms, and earlier-stage disease are evaluated for eligibility based on your diagnosis. |
| Treatment monitoring and side effect guidance | During Pembrolizumab treatment, we provide guidance on managing common side effects and red flags that warrant urgent medical attention. |
| Cross-border care coordination | If pursuing treatment in India, China, or other countries, CancerFax coordinates medical records, communication between treating teams, and logistics. |
Frequently asked questions
Common patient questions about Pembrolizumab (Keytruda)
Pembrolizumab is an immunotherapy that blocks PD-1, a checkpoint protein on immune T cells. By blocking PD-1, it helps restore the immune system's ability to recognize and attack cancer cells. This allows T cells to break through cancer's immune evasion strategies and target tumors.
Pembrolizumab is FDA-approved for many cancer types including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric cancer, urothelial carcinoma, cervical cancer, hepatocellular carcinoma, endometrial cancer, triple-negative breast cancer, colorectal cancer, and MSI-H/dMMR solid tumors. Specific approvals vary by country and regulatory setting.
Testing typically includes confirmed biopsy and histopathology, PD-L1 testing by immunohistochemistry when relevant, MSI/dMMR testing for solid tumor selection, molecular testing including NGS and mutation panels, baseline blood tests, imaging, and organ function checks.
Common side effects include fatigue, low blood counts, diarrhea or constipation, rash, and muscle cramps. These are usually manageable with dose adjustments, supportive care (blood transfusions, growth factors), and dietary changes. Serious side effects like blood clots and severe infections require urgent medical attention. Your team will monitor blood counts regularly and adjust the dose based on results and tolerability.
Pembrolizumab is not recommended during pregnancy as it may cause fetal harm. Breastfeeding should be avoided. Effective contraception is required for people of childbearing age during and after treatment. Always discuss pregnancy plans with your oncologist.
Standard intravenous Pembrolizumab infusion takes approximately 30 minutes, given every 3 weeks or every 6 weeks. The newer subcutaneous formulation (Keytruda Qlex) takes only 1 to 2 minutes, offering greater convenience and flexibility in administration settings.
If cancer progresses during or after Pembrolizumab, your oncologist may recommend repeat imaging, biomarker testing, or liquid biopsy. Next-line options include chemotherapy, targeted therapy, antibody-drug conjugates, other immunotherapies, clinical trials, or supportive care depending on cancer type.
Yes, Pembrolizumab is widely available in India through major cancer centers. Both branded Keytruda and generic Pembrolizumab from multiple manufacturers are available at significantly lower costs than in Western countries. Insurance coverage and patient assistance programs vary.